REPLIKIN COUNT VS. 5 YR. MORTALITY RATES OF HUMAN CANCERS
LONDON, UK (PRWEB) March 11, 2014
Bioradar UK Ltd. and Replikins Ltd, the companies whose software analysis of virus gene Replikin Counts predicted the H1N1 influenza pandemic of 2009 one year in advance, announced today that their new studies show that cancer of the pancreas has joined brain and lung cancer in having the highest mortality rate and the highest gene Replikin Counts yet observed. (See figure).
Replikin Counts (number of Replikins per 100 amino acids) of 250 to 325 per 100 amino acids were present in the genes of these three highest mortality cancers in proportion to the mortality rate of each (91 to 98% five year mortality rates). The high Replikin Counts, over 100, were found to be achieved by overlapping, stacking, and branching of gene Replikin structures.
These cancer gene Replikin Counts can be compared to the previously described mean human H1N1 influenza gene peak Counts of 9 to 11 during the 2009 pandemic and current outbreaks in the U.S. and Canada (approximate mortality rate <1%), and compared to mean human H5N1 influenza gene Counts of up to 30 in Egypt, Cambodia and Indonesia (mortality rates 40 to 82% (WHO)).
Thus the largest Replikins concentration yet observed has been found in human cancer genes, and this massively increased concentration has been correlated with the highest 5-year mortality rate in human cancer. Further, many of these Replikins are shared between several histological types of cancer. Replikins were first isolated from glioblastoma multiforme brain cancer cells grown in tissue culture and related to rapid replication.
These findings are being applied by Replikins Ltd. to manufacture, by solid phase synthesis, completely synthetic new cancer vaccine candidates in 7 days. In addition, the sharing of specific Replikins structures in several histological types of cancer are used to produce new trans-cancer synthetic Replikins vaccine candidates (Replikins website, Replikins Report#58, January 22, 2013).
These data will be presented at the World Vaccine Congress in Washington, D.C. March 24-26, 2014, and will be submitted for peer-reviewed publication.